- Home
- VIGL vs DCF Comparison
VIGL vs DCF Comparison
Compare VIGL & DCF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIGL
- DCF
- Stock Information
- Founded
- VIGL 2020
- DCF 2014
- Country
- VIGL United States
- DCF United States
- Employees
- VIGL N/A
- DCF N/A
- Industry
- VIGL Biotechnology: Pharmaceutical Preparations
- DCF Finance/Investors Services
- Sector
- VIGL Health Care
- DCF Finance
- Exchange
- VIGL Nasdaq
- DCF Nasdaq
- Market Cap
- VIGL 141.1M
- DCF 133.7M
- IPO Year
- VIGL 2022
- DCF N/A
- Fundamental
- Price
- VIGL $3.42
- DCF $9.12
- Analyst Decision
- VIGL Buy
- DCF
- Analyst Count
- VIGL 5
- DCF 0
- Target Price
- VIGL $16.60
- DCF N/A
- AVG Volume (30 Days)
- VIGL 121.7K
- DCF 33.2K
- Earning Date
- VIGL 08-13-2024
- DCF 01-01-0001
- Dividend Yield
- VIGL N/A
- DCF 5.25%
- EPS Growth
- VIGL N/A
- DCF N/A
- EPS
- VIGL N/A
- DCF N/A
- Revenue
- VIGL N/A
- DCF N/A
- Revenue This Year
- VIGL N/A
- DCF N/A
- Revenue Next Year
- VIGL N/A
- DCF N/A
- P/E Ratio
- VIGL N/A
- DCF N/A
- Revenue Growth
- VIGL N/A
- DCF N/A
- 52 Week Low
- VIGL $2.47
- DCF $7.25
- 52 Week High
- VIGL $9.24
- DCF $8.67
- Technical
- Relative Strength Index (RSI)
- VIGL 46.18
- DCF 71.74
- Support Level
- VIGL $3.20
- DCF $9.07
- Resistance Level
- VIGL $3.78
- DCF $9.16
- Average True Range (ATR)
- VIGL 0.30
- DCF 0.05
- MACD
- VIGL 0.03
- DCF 0.01
- Stochastic Oscillator
- VIGL 36.67
- DCF 73.91
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.
About DCF BNY Mellon Alcentra Global Credit Income 2024 Target Term Fund Inc.
BNY Mellon Alcentra Global Credit Income 2024 Target Term Fund Inc is a diversified closed-end management investment company. Its investment objectives are to seek high current income and to return at least the Fund's original NAV to holders of record of common shares on or about the termination date.